# Akebia Therapeutics

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/akebia-therapeutics/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | company in Cambridge, United States |
| OpenAlex ID | https://openalex.org/F4320330753 |
| ROR ID | https://ror.org/003br8b23 |
| Works | 396 |

## Funder papers

- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease](https://scholariq.org/papers/a-comparative-post-hoc-analysis-of-finerenone-and-spironolactone-in-resistant/)
- [Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD](https://scholariq.org/papers/correlates-and-consequences-of-an-acute-change-in-egfr-in-response-to-the-sglt2/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial](https://scholariq.org/papers/simultaneous-initiation-of-finerenone-and-empagliflozin-across-the-spectrum-of/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.